FT Value Line Dividend Index UCITS ETF UK Regulatory Announcement: Net Asset Value(s)
FT US Large Cap Core AlphaDEX ETF UK Regulatory Announcement: Net Asset Value(s)
FT FactorFX UCITS ETF Class B UK Regulatory Announcement: Net Asset Value(s)
FT FactorFX UCITS ETF UK Regulatory Announcement: Net Asset Value(s)
Rescheduling of HKTDC Book Fair and other July public fairs
Herta Launches New COVID-19 Technology for the New Normality
Presto Engineering Moves to New Facility in Caen for Enhanced Engineering and Production Capabilities
COVID-19 Impact and Recovery Analysis- Subsea Well Access And Blowout Preventer System Market 2020-2024 | Rise In Deepwater And Ultra-deepwater E&P Ac
X-FAB on Track to Resume Production After Cyber Attack
FSD Pharma Announces US$20M At-The-Market Offering
-
Renasas: Notice Regarding Conclusion of Commitment Line Agreement
TOKYO--(BUSINESS WIRE)--Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced the conclusion of a commitment line agreement as described below: 1. Purpose The objective of the agreement is, to secure flexible means of procuring financing in order to meet funding requirements for future business developments and to secure working capital, as well as to improve the stability of the Company's financial base. 2. Overview of Commitment Line Agreement Counterparties of agreement MUFG Bank, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Trust Bank, Limited., Resona Bank, Ltd. Maximum loan amount 75 billion yen Date of agreement July 13, 2020 Term of agreement Two years Collateral and guarantee No collateral or guarantees 3. Future Outlook The conclusion of this agreement will not have a material impact on Renesas’ consolidated financial results for the fiscal year ending December 31, 2020. (Reference) A commitment line is a contract whereby a financial institution promises (commits) a loan to a company within a predetermined period and maximum amount between the company and the financial institution. By entering into this agreement, Renesas will be able to procure the necessary funds in a timely manner within the set period and maximum amount. Forward-Looking Statements The statements in this press release with respect to the plans, strategies and financial outlook of Renesas Electronics and its consolidated subsidiaries (collectively “we”) are forward-looking statements involving risks and uncertainties. We caution you in advance that actual results may differ materially from such forward-looking statements due to several important factors including, but not limited to, general economic conditions in our markets, which are primarily Japan, North America, Asia, and Europe; demand for, and competitive pricing pressure on, products and services in the marketplace; ability to continue to win acceptance of products and services in these highly competitive markets; and fluctuations in currency exchange rates, particularly between the yen and the U.S. dollar. Among other factors, downturn of the world economy; deteriorating financial conditions in world markets, or deterioration in domestic and overseas stock markets, may cause actual results to differ from the projected results forecast. About Renesas Electronics Corporation Renesas Electronics Corporation (TSE: 6723) delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, infrastructure, and IoT applications that help shape a limitless future. Learn more at renesas.com. Follow us on LinkedIn, Facebook, Twitter, and YouTube. Contacts Media ContactsKyoko Okamoto Renesas Electronics Corporation +81 3-6773-3001 pr@renesas.com Investor ContactsShigeo Muto Renesas Electronics Corporation +81 3-6773-3002 ir@renesas.com
-
COVID-19: Significant Shift in Strategy of Veterinary Endoscopy Devices Market 2020-2024 | Advanced Applications of Veterinary Endoscopes to Augment G
LONDON--(BUSINESS WIRE)--#GlobalVeterinaryEndoscopyDevicesMarket--Technavio has been monitoring the veterinary endoscopy devices market and it is poised to grow by USD 104.61 million during 2020-2024, progressing at a CAGR of almost 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. B. Braun Melsungen AG, Biovision Veterinary Endoscopy LLC., FUJIFILM Holdings Corp., Hill-Rom Holdings Inc., HOYA Corp., KARL STORZ SE & Co. KG, Kirchner & Wilhelm GmbH Co. KG, MDS Inc., Olympus Corp., and STERIS Plc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free. View market snapshot before purchasing Advanced applications of veterinary endoscopes have been instrumental in driving the growth of the market. However, the high costs associated with endoscopy might hamper market growth. Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Veterinary Endoscopy Devices Market 2020-2024: Segmentation Veterinary Endoscopy Devices Market is segmented as below: Type Flexible Endoscopes Rigid Endoscopes Other Endoscopes Geography Asia Europe North America ROW To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40092 Veterinary Endoscopy Devices Market 2020-2024: Scope Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The veterinary endoscopy devices market report covers the following areas: Veterinary Endoscopy Devices Market Size Veterinary Endoscopy Devices Market Trends Veterinary Endoscopy Devices Market Industry Analysis This study identifies the development of endoscopic technologies as one of the prime reasons driving the veterinary endoscopy devices market growth during the next few years. Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio’s in-depth research has direct and indirect COVID-19 impacted market research reports. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Veterinary Endoscopy Devices Market 2020-2024: Key Highlights CAGR of the market during the forecast period 2020-2024 Detailed information on factors that will assist veterinary endoscopy devices market growth during the next five years Estimation of the veterinary endoscopy devices market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the veterinary endoscopy devices market Analysis of the market’s competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of veterinary endoscopy devices market, vendors Table of Contents: PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis Value chain analysis PART 04: MARKET SIZING Market definition Market sizing 2019 Market size and forecast 2019-2024 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Flexible endoscopes - Market size and forecast 2019-2024 Rigid endoscopes - Market size and forecast 2019-2024 Other endoscopes - Market size and forecast 2019-2024 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2019-2024 Europe - Market size and forecast 2019-2024 Asia - Market size and forecast 2019-2024 ROW - Market size and forecast 2019-2024 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing purchase of pet insurances Increasing funds for veterinary services Developments in endoscopic technologies PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors B. Braun Melsungen AG Biovision Veterinary Endoscopy LLC. FUJIFILM Holdings Corp. Hill-Rom Holdings Inc. HOYA Corp. KARL STORZ SE & Co. KG Kirchner & Wilhelm GmbH Co. KG MDS Inc. Olympus Corp. STERIS Plc PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.comWebsite: www.technavio.com/
-
New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
The second interim analysis of the STASEY study, including data from 193 people with hemophilia A, was consistent with the results from phase III HAVEN studies, with no new safety signals identified 1,2,3. STASEY is the largest open-label study to evaluate the safety and tolerability of Hemlibra in hemophilia A with factor VIII inhibitors. The data also suggest people on Hemlibra may be able to undergo certain minor surgeries without additional preventative coagulation treatment, and major surgeries could be managed with additional prophylactic coagulation factor4. TOKYO--(BUSINESS WIRE)--#hematology--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the second interim analysis results from the phase IIIb STASEY study reinforce the safety profile of Hemlibra® (emicizumab) characterized in the phase III HAVEN studies1,2,3. In the STASEY study, Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors, which was consistent with the previously reported safety profile1. The results also suggested people on Hemlibra may be able to undergo certain minor surgeries without additional preventive coagulation factor4. These results were presented at the International Society on Thrombosis and Hemostasis (ISTH) 2020 Virtual Congress (July 12 to 14, 2020). “I am pleased that the large clinical study data reinforce the long-term safety and tolerability of Hemlibra for the treatment of hemophilia A with inhibitors. The long-term data will provide great clinical insights for treatment with Hemlibra,” said Dr. Osamu Okuda, Chugai’s President and COO. “Hemlibra is a bispecific antibody drug with a novel mechanism of action, clearly distinct from existing drugs. We will continue our efforts to collect and report clinical data so that people with hemophilia A globally can continue to use Hemlibra with confidence.” The second interim analysis of the STASEY study included data from 193 participants with hemophilia A with factor VIII inhibitors, who received Hemlibra prophylaxis once-weekly1. No cases of thrombotic microangiopathy (TMA) or serious thrombotic events (TEs) related to Hemlibra were reported, and no new safety signals were observed1. Thirty-three (17.1%) people reported a Hemlibra-related adverse event (AE) 1. The most common AEs, occurring in 10% or more of people in the STASEY study, were common cold symptom nasopharyngitis (12.4%), headache (11.9%), and injection-site reaction (ISR) (11.4%)1. The ISRs reported were either mild or moderate in severity and no patients discontinued due to ISR1. Annualized bleed rates (ABR) were also consistent with previously reported observations from the phase III HAVEN studies1,2,3. A separate analysis described management and outcomes of minor and unplanned major surgeries in patients receiving Hemlibra, although not a formal surgery endpoint in STASEY. Results suggest people with hemophilia A with factor VIII inhibitors who undergo certain minor surgeries whilst receiving Hemlibra may not need additional preventative coagulation factor4. The majority of minor surgeries (n=20/31, 64.5%) were performed without the use of preventative coagulation factor and, of these, 85% (n=17/20) did not result in treated post-operative bleeds4. Of the unplanned major surgeries (n=9), eight were managed with prophylactic coagulation factor, four of which resulted in bleeds managed successfully with recombinant factor VIIa4. These findings are consistent with results observed in a previous analysis of surgeries in the pivotal HAVEN studies5. STASEY is a single-arm, multicenter, open-label, phase IIIb clinical study where participants received Hemlibra for an average of 50.9 weeks. The ABR of all bleeds, including treated bleeds, treated spontaneous bleeds, treated joint bleeds and treated target joint bleeds were low, with 167 patients (85.6%) experiencing zero treated bleeds1. There were two TEs unrelated to Hemlibra reported. One was a ST-elevation myocardial infarction in a person with pre-existing risk factors, which the treating physician assessed as unrelated to Hemlibra1. The second was a hypertrophic clot at the site of a tooth extraction, a known complication of the procedure1. There is no participation from Japan to the STASEY study. Trademarks used or mentioned in this release are protected by law. Sources Jimenez-Yuste V et al. Second Interim Analysis Results from STASEY Trial: A Single-arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluates the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII inhibitors. [poster no. PB0958] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020 Oldenburg J et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. NEJM 2017; 377:809-818. Young G et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood 2018; 132 (Supplement 1): 632. Castaman G et al. Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis. [poster no: PB0939] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020 Santagostino E et al. Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. [OC 60.1], Nurses and Orals Abstracts. Res Pract Thromb Haemost 2019; 3:1-228 Contacts For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com For European media Chugai Pharma U.K. Ltd. Tania Richards Tel: +44-20-8987-5680 E-mail: pr@chugai.eu For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp
-
Aegon to include Bank in calculation of Group Solvency II ratio
THE HAGUE, Netherlands--(BUSINESS WIRE)--Regulatory News: On July 11, the Dutch Central Bank published industry-wide guidelines regarding the treatment of banks in Solvency II ratios. As a consequence, Aegon will include Aegon Bank in the calculation of its Group Solvency II ratio going forward. This presentational change has no impact on Aegon’s capital allocation decisions. This change will be implemented ultimately by the end of 2020. The estimated negative impact of the change, based on Aegon’s capital position per March 31, 2020, is 4 percentage points on the Group Solvency II ratio, which was reported at 208%. About Aegon Aegon’s roots go back 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information on aegon.com. Forward-looking statements The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following: Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the United Kingdom; Changes in the performance of financial markets, including emerging markets, such as with regard to: The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds. Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties; Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition; Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries; The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain; Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels; Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates; Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness; Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets; Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business; The frequency and severity of insured loss events; Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products; Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results; Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations; Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations; Customer responsiveness to both new products and distribution channels; As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows; The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions; Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess cash and leverage ratio management initiatives; Changes in the policies of central banks and/or governments; Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business; Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products; Consequences of an actual or potential break-up of the European monetary union in whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union; Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers; Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates; Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); and Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels. Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Contacts Media relations Dick Schiethart+31(0) 70 344 8821 dick.schiethart@aegon.com Investor relations Jan Willem Weidema+31(0) 70 344 8028 janwillem.weidema@aegon.com
-
Novacyt S.A. ("Novacyt", the "Company" or the “Group”): Half-Year Trading Update
Sales growth of more than 900%, debt-free and significantly cashflow positive Demand for COVID-19 test expected to continue into 2021 PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the six months ended 30 June 2020. Trading update Unaudited revenue for the first half of 2020 increased over 900% to €72.4 million (£63.3 million), compared to revenue of €7.2 million (£6.3 million) for the first half of 2019, with 91% of revenue accounted for in the second quarter. For the half year, the Group estimates EBITDA profitability over €45 million (£41 million). This follows the successful launch of one of the world’s first molecular tests for COVID-19, which the Company rapidly developed and launched in January 2020. The Company’s cash position as at 30 June 2020 was €20 million (£18 million) (cash as at 31 December 2019 of €1.8 million (£1.6 million)). This strong cash position is after significant investment to meet continued demand for the COVID-19 test expected in the second half of the year. It is also reported after paying down all outstanding debt, making Novacyt debt free for the first time in the Company’s history. Demand for the Company’s COVID-19 test remains strong, with June sales of €25.4 million (£22.5 million) showing the sixth consecutive month of growth. Certain contracts for the supply of the test have also been extended into the second half of the year and in some cases into 2021. With the daily global incidence of SARS-CoV-2 infections continuing to rise, Novacyt expects significant ongoing demand for COVID-19 testing well into 2021. It is a sad fact that as of 11 July 2020, the number of global cases is more than 12.7 million, an increase of 69% compared to 11 June 2020. In the US, the Company has signed a major distribution agreement for its COVID-19 test with a new global strategic partner. The US is delivering significant sales growth for Novacyt and this new agreement enables the Company to accelerate penetration of its COVID-19 test in this important market. This distribution agreement will focus initially on the US, with the potential to expand into further markets. The Company remains well positioned to address the global need for COVID-19 testing, with its test being sold worldwide. It also has sufficient manufacturing capacity, raw materials and finished goods to meet the expected demand, having orchestrated a significant scale-up of operations during the half year. The Company continues to scale the business internally and has hired 45 people during the first half of the year, with plans to make further investment to strengthen the organisation in the second half of the year. Development of the Company’s COVID-19 test established Novacyt as a pioneer and a leader in COVID-19 diagnostics. Novacyt remains committed to building on this world-class innovative position for COVID-19 testing, and more broadly for respiratory disease testing, and is investing to address unmet needs in the market. Novacyt has already launched three new innovative products, COVID-HT, Exsig™ Direct and Exsig™ Mag, to support laboratories testing for COVID-19. These products are expected to drive incremental revenue and the Company received initial orders in June 2020 following their launch. Novacyt expects to provide an update on its investment in R&D to support continued growth, including a number of new products and innovations to be launched in the near future. Outlook Given the visibility of orders, extended contracts and the launch of new COVID-19 related products, the Company anticipates revenue for the second half of the year to be greater than the first half of the year and margins to be at least at a similar level. As a result, there is expected to be greater cash generation in the second half of the year and the Company is reviewing its capital allocation policy to enhance and accelerate long-term value creation through its three-pillar strategy of organic, R&D and acquisitive growth. Graham Mullis, Group CEO of Novacyt, commented: “The first half of 2020 has been transformational for Novacyt. The Company has rapidly established itself as one of the market leaders in COVID-19 PCR testing, with a significantly increased customer base, a recognised reputation for the performance of its products and established multiple significant strategic partnerships. This solid foundation, combined with a strong financial performance, will enable us to greatly enhance and accelerate our strategy for delivering long-term value to shareholders. I look forward to providing an update on these plans as we move into this exciting next phase of growth for the Company.” This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. About Novacyt Group The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates. For more information please refer to the website: www.novacyt.com Contacts Novacyt SAGraham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470 Allegra Finance (French Listing Sponsor)Rémi Durgetto / Yannick Petit +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com; y.petit@allegrafinance.com FTI Consulting (International)Victoria Foster Mitchell / Mary Whittow +44 (0)20 3727 1000 victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com FTI Consulting (France)Arnaud de Cheffontaines +33 (0)147 03 69 47 arnaud.decheffontaines@fticonsulting.com
-
Aegon to include Bank in calculation of Group Solvency II ratio
THE HAGUE, Netherlands--(BUSINESS WIRE)--On July 11, the Dutch Central Bank published industry-wide guidelines regarding the treatment of banks in Solvency II ratios. As a consequence, Aegon will include Aegon Bank in the calculation of its Group Solvency II ratio going forward. This presentational change has no impact on Aegon’s capital allocation decisions. This change will be implemented ultimately by the end of 2020. The estimated negative impact of the change, based on Aegon’s capital position per March 31, 2020, is 4 percentage points on the Group Solvency II ratio, which was reported at 208%. About Aegon Aegon’s roots go back 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information on aegon.com. Forward-looking statements The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following: Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the United Kingdom; Changes in the performance of financial markets, including emerging markets, such as with regard to: The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds. Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties; Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition; Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries; The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain; Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels; Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates; Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness; Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets; Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business; The frequency and severity of insured loss events; Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products; Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results; Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations; Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations; Customer responsiveness to both new products and distribution channels; As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows; The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions; Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess cash and leverage ratio management initiatives; Changes in the policies of central banks and/or governments; Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business; Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products; Consequences of an actual or potential break-up of the European monetary union in whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union; Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers; Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates; Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); and Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels. Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Contacts Media relations Dick Schiethart+31(0) 70 344 8821 dick.schiethart@aegon.com Investor relations Jan Willem Weidema+31(0) 70 344 8028 janwillem.weidema@aegon.com
-
Bega Cheese selects Software AG to provide IoT dairy supply chain solution
SINGAPORE, Jul 13, 2020 - (ACN Newswire) - Software AG today announced it has been selected by Bega Cheese to provide its Cumulocity IoT solution to Bega Cheese to launch a new IoT service linking the company's farmer suppliers, milk transport and storage, and processing facilities.The deal will see Software AG providing Bega Cheese with IoT solutions to provide real time data on milk production at farmer suppliers including volumes, temperature, quality composition, and transport conditions, to gain efficiencies in pickup and delivery frequency to reduce costs and improve traceability.According to Adel Salman, GM Supply Chain at Bega Cheese, the company knew that IoT could be an excellent solution, especially with the use of real-time data for both inbound and outbound activities in the company's supply chain."What we didn't have was experience in setting up IoT projects, so we started looking around for a partner that could provide us with IoT expertise, resources, industry contacts and help with government backing," said Salman."Swinburne University of Technology with its Internet of Things Lab and Industry 4.0 initiatives as well as its research partnership with Software AG was the perfect collaborator for us. Swinburne University listened to what we needed to achieve and together with Software AG, developed an IoT strategy with a set of solutions that met our needs. The university has also been instrumental in helping us to successfully apply for a research grant from the federal government's Cooperative Research Centres Projects (CRC-P)," added Salman.Tony Drewitt, Head of IoT ANZ, Software AG, said: "We're excited to have this opportunity to work with Bega Cheese, one of Australia's largest dairy producers. The work Bega Cheese is doing in the milk supply chain area is revolutionary. With Cumulocity, Bega Cheese will have real-time data and insights which will allow it to enhance its supply chain productivity and competitiveness with just-in-time milk pickup and processing requirements on a large scale." The scope of the project will include:- a novel low-cost milk quality sensor enabled for IoT- an IoT 'live' Supply Chain Monitoring system for continuous real-time monitoring of milk supply quantity and quality, farm conditions (i.e. humidity and temperature) affecting milk production, and milk pickup events across the supply chain- a Dynamic Pickup Scheduling and Monitoring tool that utilises sensor data reporting milk supply change events to automatically maintain optimal pickup schedules, and pickup events to monitor schedule and process adherence- a predictive machine learning-based Highly Accurate Forecasting tool for milk quality and quantity that exploits live and long-term historical data from sensors across the supply chain- a Farmer App that provides milk forecasting together with milk quality and pickup alertsSwinburne University will also develop and build unique new IoT sensors specifically for Bega Cheese."We're excited to see the benefits that IoT can bring to our company. By working with Swinburne University and Software AG, we hope to be able to increase our growth across higher-value premium products thus enhancing the competitiveness for both Bega and our suppliers," said Salman."We also aim to increase the company's supply chain sustainability by reducing milk wastage and fuel consumption of our milk transport partners."The project is expected to run for a period of 12 to 18 months.About Software AGSoftware AG reimagines integration, sparks business transformation and enables fast innovation on the Internet of Things so you can pioneer differentiating business models. We give you the freedom to connect and integrate any technology from app to edge. We help you free data from silos so it's shareable, usable and powerful - enabling you to make the best decisions and unlock entirely new possibilities for growth. Visit our site to learn more Software AG's Cumulocity IoT and webMethods Integration Platform solutions. Learn more about Software AG at www.softwareag.com. Follow us on LinkedIn and Twitter.About Bega CheeseBega Cheese is an Australian diversified food company and one of the largest dairy producers in the country. It was originally founded as a dairy cooperative in 1899 with a number of its shares still held by Bega's farmer-suppliers. Headquartered in Bega, and with manufacturing sites in New South Wales, Queensland and Victoria, over half of Bega Cheese's revenue (as of 2019) comes from its spreads, dairy consumer packaged goods and other grocery products.Media ContactMichelle BongPRecious CommunicationsM: +61 422 966 013E: michelle@preciouscomms.com Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
-
Burden of COVID-19 on the Market & Rehabilitation Plan | Artificial Intelligence (AI) Market in Manufacturing Industry 2019-2023 | The Increasing Use
LONDON--(BUSINESS WIRE)--#ArtificialIntelligenceAIMarketinManufacturingIndustry--Technavio has been monitoring the artificial intelligence (AI) market in manufacturing industry and it is poised to grow by USD 7.22 billion during 2019-2023, progressing at a CAGR of about 31% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Amazon Web Services Inc., FANUC Corp., General Electric Co., Google LLC, H2O.ai Inc., IBM Corp., KUKA Aktiengesellschaft, Microsoft Corp., Rockwell Automation Inc., and SAP SE. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free. View market snapshot before purchasing The increasing use of industrial IoT has been instrumental in driving the growth of the market. However, data privacy and compliance maintenance might hamper market growth. Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. https://www.technavio.com/report/artificial-intelligence-market-in-manufacturing-industry-analysis?tnplus Artificial Intelligence (AI) Market in Manufacturing Industry 2019-2023: Segmentation Artificial Intelligence (AI) Market in Manufacturing Industry is segmented as below: Application Predictive Maintenance And Machine Inspection Production Planning Quality Control Others Geography APAC Europe MEA North America South America To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR32119 Artificial Intelligence (AI) Market in Manufacturing Industry 2019-2023: Scope Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The artificial intelligence (AI) market in manufacturing industry report covers the following areas: Artificial Intelligence (AI) Market in Manufacturing Industry Size Artificial Intelligence (AI) Market in Manufacturing Industry Trends Artificial Intelligence (AI) Market in Manufacturing Industry Analysis This study identifies the increasing human-robot collaboration as one of the prime reasons driving the artificial intelligence (AI) market growth in manufacturing industry during the next few years. Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio’s in-depth research has direct and indirect COVID-19 impacted market research reports. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Artificial Intelligence (AI) Market in Manufacturing Industry 2019-2023: Key Highlights CAGR of the market during the forecast period 2019-2023 Detailed information on factors that will assist artificial intelligence (AI) market growth in manufacturing industry during the next five years Estimation of the artificial intelligence (AI) market size in manufacturing industry and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the artificial intelligence (AI) market in manufacturing industry Analysis of the market’s competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of artificial intelligence (AI) market industry vendors in manufacturing industry Table of Contents: PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Predictive maintenance and machine inspection - Market size and forecast 2018-2023 Production planning - Market size and forecast 2018-2023 Quality control - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison APAC - Market size and forecast 2018-2023 North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 South America - Market size and forecast 2018-2023 MEA - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DRIVERS AND CHALLENGES Market drivers Market challenges PART 10: MARKET TRENDS Advancements in AI related to intelligent business process Increasing human-robot collaboration Growing demand for generative designs PART 11: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 12: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Amazon Web Services, Inc. FANUC Corp. General Electric Co. Google LLC H2O.ai Inc. IBM Corp. KUKA Aktiengesellschaft Microsoft Corp. Rockwell Automation Inc. SAP SE PART 13: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 14: EXPLORE TECHNAVIO About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.comWebsite: www.technavio.com/
-
Oriental Yuhong Obtains an Invention Patent in Singapore after One in the US
BEIJING, July 12, 2020 /PRNewswire/ -- Oriental Yuhong's product - HDPE polymer waterproof coiled material - has recently obtained a patent (patent NO. 11201705060T) issued by the Intellectual Property Office of Singapore. Last year, its product of the same series was granted a patent (patent NO. 11201705060T) by the IP Australia and a patent by the United States Patent and Trademark Office (patent NO. US10487215). Patent application In 2019, Oriental Yuhong broke the European and American monopoly and participated in the construction of a subway in Singapore. The subway – ThomsonLine – is 30 kilometers long. In order to solve the problem of underground leakage, Oriental Yuhong provided a professional waterproof solution and adopted HDPE self-adhesive film waterproof coiled material for waterproof construction. Due to the regional requirements and protection of the product patent, Oriental Yuhong applied for a patent on its HDPE product in Singapore in advance. The high-performance, multi-material, multi-layer waterproof protection technology for underground waterproof protection with this patent as the core solves the bottleneck problem of water leakage of traditional waterproof protection technology, promotes the progress of underground waterproof protection technology, and enhances Oriental Yuhong's international technological competitiveness. The technology won a class-II prize in the National Award for Scientific and Technological Progress in 2019. The HDPE products are suitable for all kinds of underground waterproof projects. Projects at home and abroad over the past 30 years have showed that Oriental Yuhong's HDPE polymer self-adhesive film waterproof coiled material and underground pre-laying anti-adhesive waterproof construction technology, which are suitable for most of the underground spaces - subways, tunnels, pipe corridors, nuclear power and other fields - have been used in projects like South-to-North Water Diversion, Liupanshui Underground Comprehensive Pipe Corridor, Beijing-Shanghai High-Speed Railway and Beijing-Kaifeng Subway, and have been exported to the US, India, Singapore, Malaysia, Indonesia and other foreign countries, have been recognized by more and more customers. With 1 million square meters of waterproof materials sold internationally every year, Oriental Yuhong is getting more and more recognition and attention. Oriental Yuhong always regards scientific and technological innovation as its core competitiveness and attaches great importance to intellectual property protection. It will also apply for patents on its HDPE products in other countries. As of July 1, the Group has totally had 957 valid patents (including 291 inventions, 553 utility models and 113 designs), and 12 PCT international applications. Related Links :http://www.yuhong.com.cn
-
New Data From Phase IIIb Study Reinforces Safety Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Hemophilia A
– Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from Phase III HAVEN studies, with no new safety signals identified – – STASEY is the largest open-label study primarily assessing safety and tolerability of a medicine for hemophilia A with factor VIII inhibitors – – A separate analysis also suggests people on Hemlibra may be able to undergo certain minor surgeries without additional preventative coagulation treatment and major surgeries could be managed with additional prophylactic coagulation factor – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the second interim analysis of the Phase IIIb STASEY study, which reinforce the safety profile of Hemlibra® (emicizumab-kxwh) characterized in the Phase III HAVEN clinical program. In the STASEY study, Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors, which was consistent with previous safety observations. Further new interim data suggest that people on Hemlibra may be able to undergo certain minor surgeries without additional preventative (prophylactic) coagulation factor. These data were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress, July 12-14, 2020. “These important safety data continue to add to the extensive clinical evidence reinforcing Hemlibra’s potential to redefine the standard of care for people with hemophilia A,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The STASEY study reflects our continued focus on providing valuable insights that meet the needs of the hemophilia community and enhance our understanding of Hemlibra in clinical practice.” The second interim analysis of the STASEY study included data from 193 patients with hemophilia A with factor VIII inhibitors, who received Hemlibra prophylaxis once-weekly. No cases of thrombotic microangiopathy or serious thrombotic events (TEs) related to Hemlibra were reported, and no new safety signals were observed. Thirty-three (17.1%) people reported a Hemlibra-related adverse event (AE). The most common AEs, occurring in 10% or more of people in the STASEY study, were common cold symptoms nasopharyngitis; (12.4%), headache (11.9%) and injection site reactions (ISRs) (11.4%). The ISRs reported were either mild or moderate in severity and no patients discontinued due to ISR. Annualized bleeding rates (ABR) were also consistent with previously reported observations from the Phase III HAVEN studies. A separate analysis described management and outcomes of minor and unplanned major surgeries in patients receiving Hemlibra, although there was not a formal surgery endpoint in STASEY. Results suggest people with hemophilia A with factor VIII inhibitors who undergo certain minor surgeries while receiving Hemlibra may not need additional preventative (prophylactic) coagulation factor. The majority of minor surgeries (n=20/31) were performed without the use of prophylactic coagulation factor (64.5%) and, of these, 85% (n=17/20) did not result in treated post-operative bleeds. Of the unplanned major surgeries (n=9), eight were managed with prophylactic coagulation factor, four of which resulted in bleeds managed successfully with recombinant factor VIIa. These findings are consistent with results observed in a previous analysis of surgeries in the pivotal HAVEN studies. STASEY is a single-arm, multicenter, open-label, Phase IIIb clinical study where patients received Hemlibra for an average of 50.9 weeks. The ABR of all bleeds, including treated bleeds, treated spontaneous bleeds, treated joint bleeds and treated target joint bleeds were low, with 167 patients (85.6%) experiencing zero treated bleeds. In the STASEY study there were two TEs unrelated to Hemlibra reported. One was a ST-elevation myocardial infarction in a person with pre-existing risk factors, which the treating physician assessed as unrelated to Hemlibra. The second was a hypertrophic clot at the site of a tooth extraction, a known complication of the procedure. Hemlibra is approved to treat people with hemophilia A with factor VIII inhibitors in more than 90 countries worldwide and for people without factor VIII inhibitors in more than 70 countries worldwide, including the U.S., EU and Japan. Hemlibra has been studied in one of the largest clinical trial programs in people with hemophilia A with and without factor VIII inhibitors, including five completed Phase III studies. The STASEY study is the largest open-label study primarily assessing the safety and tolerability of a medicine for people with hemophilia A with factor VIII inhibitors. About Hemlibra Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for hemophilia A patients. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once weekly, every two weeks or every four weeks. Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. Hemlibra U.S. Indication Hemlibra is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors. Important Safety Information What is the most important information to know about Hemlibra? Hemlibra increases the potential for blood to clot. Patients should carefully follow their healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. Hemlibra may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including: Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to one's kidneys, brain, and other organs. Patients should get medical help right away if they have any of the following signs or symptoms during or after treatment with Hemlibra: confusion weakness swelling of arms and legs yellowing of skin and eyes stomach (abdomen) or back pain nausea or vomiting feeling sick decreased urination Blood clots (thrombotic events). Blood clots may form in blood vessels in the arm, leg, lung, or head. Patients should get medical help right away if they have any of these signs or symptoms of blood clots during or after treatment with Hemlibra: swelling in arms or legs pain or redness in the arms or legs shortness of breath chest pain or tightness fast heart rate cough up blood feel faint headache numbness in the face eye pain or swelling trouble seeing If aPCC (FEIBA®) is needed, patients should talk to their healthcare provider in case they feel they need more than 100 U/kg of aPCC (FEIBA®) total. Before using Hemlibra, patients should tell their healthcare provider about all of their medical conditions, including if they: are pregnant or plan to become pregnant. It is not known if Hemlibra may harm an unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with Hemlibra. are breastfeeding or plan to breastfeed. It is not known if Hemlibra passes into breast milk. Patients should tell their healthcare provider about all the medicines they take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Patients should keep a list of them to show their healthcare provider and pharmacist when they get a new medicine. How should patients use Hemlibra? Patients should see the detailed “Instructions for Use” that comes with Hemlibra for information on how to prepare and inject a dose of Hemlibra, and how to properly throw away (dispose of) used needles and syringes. Stop (discontinue) prophylactic use of bypassing agents the day before starting Hemlibra prophylaxis. Patients may continue prophylactic use of factor VIII for the first week of Hemlibra prophylaxis. What should patients know about lab monitoring? Hemlibra may interfere with laboratory tests that measure how well blood is clotting and may cause a false reading. Patients should talk to their healthcare provider about how this may affect their care. The most common side effects of Hemlibra include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain. These are not all of the possible side effects of Hemlibra. Patients should speak to their healthcare provider for medical advice about side effects. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Patients should not use Hemlibra for a condition for which it was not prescribed. Patients should not give Hemlibra to other people, even if they have the same symptoms that they have. It may harm them. Patients can ask their pharmacist or healthcare provider for information about Hemlibra that is written for health professionals. Side effects may be reported to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Side effects may also be reported to Genentech at (888) 835-2555. Please see the Hemlibra full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects. About hemophilia A Hemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Hemophilia affects around 20,000 people in the United States, with hemophilia A being the most common form and approximately 50-60 percent of people living with a severe form of the disorder. People with hemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their disorder, people with hemophilia A can bleed frequently, especially into their joints or muscles. These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility and long-term joint damage. A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies. Inhibitors are antibodies developed by the body’s immune system that bind to and block the efficacy of replacement factor VIII, making it difficult, if not impossible, to obtain a level of factor VIII sufficient to control bleeding. About Genentech in hemophilia In 1984, Genentech scientists were the first to clone recombinant factor VIII in response to the contaminated hemophilia blood supply crisis of the early 1980s. For more than 20 years, Genentech has been developing medicines to bring innovative treatment options to people with diseases of the blood within oncology, and in hemophilia A. Genentech is committed to improving treatment and care in the hemophilia community by delivering meaningful science and clinical expertise. For more information visit http://www.gene.com/hemophilia. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com. Contacts Media Contact:Adam Pryor (650) 467-6800 Advocacy Contact: Sonali Chopra (650) 467-0842 Investor Contacts: Loren Kalm (650) 225-3217 Karl Mahler 011 41 61 687 8503
-
COVID-19 Impact & Recovery Analysis- Digital Asset Management Market (2020-2024) | Shift From On Premises To SaaS to Boost Growth | Technavio
LONDON--(BUSINESS WIRE)--#DigitalAssetManagementMarket--Technavio has been monitoring the digital asset management market and it is poised to grow by $ 6.59 bn during 2020-2024, progressing at a CAGR of 23% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact The market is concentrated, and the degree of concentration will accelerate during the forecast period. Adobe Inc., Bynder BV, Cognizant Technology Solutions Corp., Dell Technologies Inc., HP Inc., Huawei Investment and Holding Co. Ltd., International Business Machines Corp., Microsoft Corp., Open Text Corp., and Tata Consultancy Services Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Shift from on premises to SaaS has been instrumental in driving the growth of the market. However, data privacy and security concerns might hamper market growth. Digital Asset Management Market 2020-2024 : Segmentation Digital Asset Management Market is segmented as below: Type On Premises Cloud Geography North America Europe APAC South America MEA To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43522 Digital Asset Management Market 2020-2024 : Scope Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our digital asset management market report covers the following areas: Digital Asset Management Market size Digital Asset Management Market trends Digital Asset Management Market industry analysis This study identifies increased adoption of analytics to manage digital assets as one of the prime reasons driving the digital asset management market growth during the next few years. Digital Asset Management Market 2020-2024 : Vendor Analysis We provide a detailed analysis of around 25 vendors operating in the digital asset management market, including some of the vendors such as Adobe Inc., Bynder BV, Cognizant Technology Solutions Corp., Dell Technologies Inc., HP Inc., Huawei Investment and Holding Co. Ltd., International Business Machines Corp., Microsoft Corp., Open Text Corp., and Tata Consultancy Services Ltd. Backed with competitive intelligence and benchmarking, our research reports on the digital asset management market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Digital Asset Management Market 2020-2024 : Key Highlights CAGR of the market during the forecast period 2020-2024 Detailed information on factors that will assist digital asset management market growth during the next five years Estimation of the digital asset management market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the digital asset management market Analysis of the market’s competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of digital asset management market vendors Table Of Contents : Executive Summary Market Landscape Market ecosystem Value chain analysis Market Sizing Market definition Market segment analysis Market size 2019 Market outlook: Forecast for 2019 - 2024 Five Forces Analysis Five forces summary Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition Market Segmentation by Type Market segments Comparison by Type On premises - Market size and forecast 2019-2024 Cloud - Market size and forecast 2019-2024 Market opportunity by Type Customer Landscape Geographic Landscape Geographic segmentation Geographic comparison North America - Market size and forecast 2019-2024 Europe - Market size and forecast 2019-2024 APAC - Market size and forecast 2019-2024 South America - Market size and forecast 2019-2024 MEA - Market size and forecast 2019-2024 Key leading countries Market opportunity by geography Volume Drivers – Demand-led growth Market Challenges Market Trends Vendor Landscape Vendor landscape Landscape disruption Vendor Analysis Vendors covered Market positioning of vendors Adobe Inc. Bynder BV Cognizant Technology Solutions Corp. Dell Technologies Inc. HP Inc. Huawei Investment and Holding Co. Ltd. International Business Machines Corp. Microsoft Corp. Open Text Corp. Tata Consultancy Services Ltd. Appendix Scope of the report Currency conversion rates for US$ Research methodology List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.comWebsite: www.technavio.com/
-
Genentech Provides Update on Phase III Study of Tecentriq in Women With Advanced-stage Ovarian Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination. “Ovarian cancer remains one of the most aggressive cancers and is difficult to treat in its advanced stages,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “While we are disappointed by these results, we remain committed to improving outcomes for women living with this disease and are pleased that Avastin remains a key component in the treatment of front-line ovarian cancer.” Data for the overall survival (OS) co-primary endpoint are currently immature and follow-up will continue until the next planned analysis. Results from IMagyn050 will be further evaluated in order to inform the Tecentriq gynecological development program. The Tecentriq program in ovarian cancer and cervical cancers builds on the combination with Avastin, which has helped women with newly diagnosed, advanced or relapsed ovarian and cervical cancers live without their disease getting worse, as demonstrated in results across seven pivotal Phase III trials that involved more than 5,000 women. Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines. About the IMagyn050 study IMagyn050 is a Phase III, multicenter, randomized, double-blind study evaluating the efficacy and safety of Tecentriq in combination with Avastin, paclitaxel and carboplatin compared to placebo plus Avastin, paclitaxel and carboplatin in women with stage III or IV ovarian cancer who are undergoing neoadjuvant or adjuvant therapy. Patients were randomized 1:1 either before or after tumor reductive surgery. The co-primary endpoints are investigator-determined PFS and OS, both in the intent-to-treat (ITT) population and PD-L1-positive subpopulation. Key secondary endpoints include objective response rate, safety and tolerability, as well as patient-reported improvement in abdominal pain and bloating. The IMagyn050 study is being conducted in collaboration with The GOG Foundation, Inc. (GOG Foundation) [GOG-3015] and the European Network of Gynaecological Oncological Trial groups (ENGOT) [ENGOT OV-39]. About ovarian cancer According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women. This year, an estimated 21,000 women will be diagnosed with ovarian cancer and 14,000 will die from the disease. Ovarian cancer remains the leading cause of death from any gynecological malignancy, as the majority of patients are not diagnosed until they present with already advanced-stage disease, resulting in a 5-year survival rate of less than 30%. About Tecentriq® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. About Avastin® (bevacizumab) Avastin is a prescription-only medicine that is a solution for intravenous infusion. It is a biologic antibody designed to specifically bind to a protein called VEGF that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize). Tecentriq U.S. Indications (pronounced ‘tē-SEN-trik’) Tecentriq is a prescription medicine used to treat adults with: A type of bladder and urinary tract cancer called urothelial carcinoma. Tecentriq may be used in patients with urothelial carcinoma if their bladder cancer has spread or cannot be removed by surgery, and if they have any one of the following conditions: They are not able to take chemotherapy that contains a medicine called cisplatin and their cancer tests positive for “PD-L1” or They are not able to take chemotherapy that contains any platinum regardless of the levels of “PD-L1” status or They have tried chemotherapy that contains platinum and it did not work or is no longer working The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients’ disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit. A type of lung cancer called non-small cell lung cancer (NSCLC). Tecentriq may be used alone as the first treatment in patients with lung cancer if: Their cancer has spread or grown and Their cancer tests positive for “high PD-L1,” and Their tumor does not have an abnormal “EGFR” or “ALK” gene. Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as the first treatment in patients with lung cancer if: Their cancer has spread or grown, and Is a type called “non-squamous NSCLC.” and Their tumor does not have an abnormal “EGFR” or “ALK” gene. Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as the first treatment in patients with lung cancer if: Their cancer has spread or grown, and Is a type called “non-squamous NSCLC,” and Their tumor does not have an abnormal “EGFR” or “ALK” gene. Tecentriq may be used alone in patients with lung cancer if: Their cancer has spread or grown and They have tried chemotherapy that contains platinum, and it did not work or is no longer working If a patient’s tumor has an abnormal EGFR or ALK gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working. A type of breast cancer called triple-negative breast cancer (TNBC). Tecentriq may be used with the medicine paclitaxel protein-bound in patients with TNBC when their breast cancer: Has spread or cannot be removed by surgery and Their cancer tests positive for “PD-L1” The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients’ disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit. A type of lung cancer called small cell lung cancer (SCLC). Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as the first treatment in patients with SCLC when their lung cancer is a type of lung cancer called “extensive-stage small cell lung cancer,” which means that it has spread or grown. A type of liver cancer called hepatocellular carcinoma (HCC). Tecentriq may be used with the medicine bevacizumab when a patient’s liver cancer: has spread or cannot be removed by surgery, and the patient has not received other medicines by mouth or injection through their vein (IV) to treat their cancer. It is not known if Tecentriq is safe and effective in children. Important Safety Information The most important information about Tecentriq is: Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse. Tecentriq can cause serious side effects, including: Lung problems (pneumonitis)–signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath and chest pain Liver problems (hepatitis)–signs and symptoms of hepatitis may include yellowing of the skin or the whites of the eyes, severe nausea or vomiting, pain on the right side of the stomach area (abdomen), drowsiness, dark urine (tea-colored), bleeding or bruising more easily than normal and feeling less hungry than usual Intestinal problems (colitis)–signs and symptoms of colitis may include diarrhea (loose stools) or more bowel movements than usual; blood or mucus in stools or dark, tarry, sticky stools; and severe stomach area (abdomen) pain or tenderness Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary)–signs and symptoms that the hormone glands are not working properly may include headaches that will not go away or unusual headaches, extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss, changes in mood or behavior (such as decreased sex drive, irritability, or forgetfulness), feeling cold, constipation, the voice gets deeper, urinating more often than usual, nausea or vomiting and stomach area (abdomen) pain Problems in other organs–signs and symptoms may include severe muscle weakness, numbness or tingling in hands or feet, confusion, blurry vision, double vision, or other vision problems, changes in mood or behavior, extreme sensitivity to light, neck stiffness, eye pain or redness, skin blisters or peeling, chest pain, irregular heartbeat, shortness of breath or swelling of the ankles Severe infections–signs and symptoms of infection may include fever, cough, flu-like symptoms, pain when urinating and frequent urination or back pain Severe infusion reactions–signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, swelling of the face or lips, dizziness, fever, feeling like passing out and back or neck pain Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment with Tecentriq if patients have severe side effects. Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they: Have immune system problems (such as Crohn’s disease, ulcerative colitis, or lupus); have had an organ transplant; have lung or breathing problems; have liver problems; have a condition that affects the nervous system (such as myasthenia gravis or Guillain-Barre syndrome); or are being treated for an infection Are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant: Should have a healthcare provider do a pregnancy test before they start treatment with Tecentriq and Should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq Are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq. Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of Tecentriq when used alone include: Feeling tired or weak Nausea Cough Shortness of breath Decreased appetite The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include: Feeling tired or weak Nausea Hair loss Constipation Diarrhea Decreased appetite The most common side effects of Tecentriq when used in TNBC with paclitaxel protein-bound include: Hair loss Tingling or numbness in hands and feet Feeling tired Nausea Diarrhea Low red blood cells (anemia) Constipation Cough Headache Low white blood cells Vomiting Decreased appetite The most common side effects of Tecentriq when used in hepatocellular carcinoma with bevacizumab include: High blood pressure Feeling tired or weak Too much protein in the urine Tecentriq may cause fertility problems in females, which may affect their ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility. These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information. Patients should call their doctor for medical advice about side effects of Tecentriq. Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555. Please visit http://www.Tecentriq.com for the full Prescribing Information and for additional Important Safety Information. Avastin U.S. Indications Avastin is approved for: Metastatic colorectal cancer (mCRC) for first- or second-line treatment in combination with intravenous fluorouracil–based chemotherapy. It is also approved to treat mCRC for second-line treatment, when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy, after cancer progresses following a first-line treatment that includes Avastin Avastin is not approved for use after surgery was used as the primary treatment in patients with colon cancer which has not spread to other parts of the body. Advanced nonsquamous non–small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel, in people who have not received chemotherapy for their advanced disease Metastatic kidney cancer (mRCC) when used with interferon alfa Glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM) Advanced cervical cancer (CC) in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix Hepatocellular Carcinoma (HCC) - Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy Ovarian cancer (OC) - Avastin, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery Avastin in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (prOC) in women who received no more than two prior chemotherapy treatments. Avastin, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (psOC). Possible serious side effects Everyone reacts differently to Avastin therapy. So, it’s important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Their doctor will stop treatment if any serious side effects occur. Patients should contact their health care team if there are any signs of these side effects. GI perforation. A hole that develops in the stomach or intestine. Symptoms include pain in the abdomen, nausea, vomiting, constipation, or fever Abnormal passage in the body. This type of passage-known as a fistula-is an irregular connection from one part of the body to another and can sometimes be fatal Wounds that don’t heal. A cut made during surgery can be slow to heal or may not fully heal. Avastin should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If a patient has recently coughed up blood or had serious bleeding, they should be sure to tell their doctor Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on Avastin and after stopping treatment Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal Infusion-related reactions. These were uncommon with the first dose (less than 3% of patients). 0.2% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. The patient’s doctor or nurse will monitor for signs of infusion reactions Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and the heart may become too weak to pump blood to other parts of the body (congestive heart failure). These can sometimes be fatal Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness Side effects seen most often In clinical studies across different types of cancer, some patients experienced the following side effects: High blood pressure Too much protein in the urine Nosebleeds Rectal bleeding Back pain Headache Taste change Dry skin Inflammation of the skin Inflammation of the nose Watery eyes Avastin is not for everyone Patients should talk to their doctor if they are: Undergoing surgery. Avastin should not be used for 28 days before or after surgery and until surgical wounds are fully healed Pregnant or think they are pregnant. Data have shown that Avastin may harm a woman’s unborn baby. Birth control should be used while patients are on Avastin. If Avastin is stopped, patients should keep using birth control for 6 months before trying to become pregnant Planning to become pregnant. Taking Avastin could cause a woman’s ovaries to stop working and may impair her ability to have children Breastfeeding. Breastfeeding while on Avastin may harm the baby, therefore women should not breastfeed during and for 6 months after taking Avastin Patients should talk with their doctor if they have any questions about their condition or treatment. Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at 1-888-835-2555. For full Prescribing Information and Boxed WARNINGS on Avastin please visit http://www.avastin.com. About Genentech in cancer immunotherapy Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system. In addition to Genentech’s approved PD-L1 checkpoint inhibitor, the company’s broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com. Contacts Media Contact: K. Bruneau (650) 467-6800 Advocacy Contact: Lauren Davis (650) 745-5210 Investor Contacts: Loren Kalm (650) 225-3217 Karl Mahler 011 41 61 687 8503
-
Sales of Cardio-Cerebrovascular Products and Lianhua Qingwen Surge, Yiling Pharmaceutical Predicting a 50% Increase in Half-year Net Profit
SHIJIAZHUANG, China, July 13, 2020 /PRNewswire/ -- In the evening of July 12, Yiling Pharmaceutical released the performance forecast for the first half year. In the first half of this year, the company achieved a net profit attributable to shareholders of 682 million to 728 million Yuan (USD 97.4 million to 104 million), an annual increase of 50%-60%, with basic earnings of 0.57 - 0.60 Yuan per share, and the strong growth momentum of the first quarter persists. In 2019 Yiling Pharmaceutical achieved a net profit of 606.5 million Yuan. The net profit of the first half in this year already exceeds that of the whole year last year. According to Yiling Pharmaceutical, there are two main reasons accounting for the surge in revenue: On the one hand, sales revenue of Lianhua Qingwen in the first half of this year saw a rapid growth compared with the same period last year. Lianhua Qingwen has also experienced a remarkable year-over-year rise in sales in the second quarter as the popularity and reputation of the product advance at home and abroad. On the other hand, the outbreak of COVID-19 was well contained in the second quarter, coupled with the fact that the company was granted the First Prize of China's National Science and Technology Progress, which has greatly enhanced the influence of the company on the market of cardio-cerebrovascular products. The sales revenue of these products achieved growth in the second quarter. The Second Quarter Performance Exceeds Market Expectations Yiling Pharmaceutical's performance forecast of the first-half of this year has attracted widespread attention in the market. Due to COVID-19, it was generally believed that the growth rate in the first quarter would serve as the peak of this year's growth. With the domestic outbreak well under control in the second quarter, the company's growth rate would go downward quarter by quarter, but according to the company's performance forecast of the first half year, the growth rate in the second quarter could very likely be surpassing that of the first quarter, which exceeds the market expectations. The published statistics show that in the first quarter of this year, Yiling Pharmaceutical achieved an operating revenue of 2.334 billion Yuan, a year-on-year increase of 50.56%. The net profit attributed to shareholders was 437 million Yuan, up by 51.88% year-on-year. "Judging from the trend of net profit of Yiling Pharmaceutical in recent years, it is estimated that the revenue growth rate in the second quarter should also be more than 50%, with which the company will further consolidate its leading position in the traditional Chinese medicine industry", said a brokerage analyst. At the end of the first half year of 2020, the financial data company Wind released a list of "Top 500 Publicly Traded Chinese Companies for the First Half Year 2020". The statistics were collected until June 30. The entry threshold of the list this year was risen to 31.2 billion Yuan, an increase of 5.1 billion Yuan compared with 26.1 billion Yuan in the first quarter. Yiling Pharmaceutical made the list with a market value of 37.5 billion Yuan, an increase of 150% in market value, moving up 583 places in the ranking. Cardiovascular Product Sales Growing Against the Market Trend In addition to the Lianhua Qingwen boom, sales revenue of cardiovascular products of Yiling Pharmaceutical has also been climbing against the market trend in the second quarter, which is also worthy of attention. Although the coronavirus outbreak was already tamed during the second quarter, yet the number of outpatient visits to most hospitals hadn't return to the previous years' level in the same period of time due to precautionary measures concerning COVID-19 and other factors. According to the "Investigation of the Operating State of Chinese Social Medical Institutions during the Outbreak of COVID-19 in 2020", jointly conducted by the Medical Management Research Center of "Medical Industry Observe" and the Institute of Social Medical Institutions of Shanghai Jiaotong University, only 6.6% of the sample hospitals had a number of outpatient visits till May comparable or higher than that in the same period last year; 36.9% of the hospitals resumed more than 80% of the outpatient visits of that in the same period last year; and more than 30% of the hospitals failed to recover even 50% of the figure in the same period last year. The decline in outpatient visits led directly to a decrease in sales revenue for the majority of drugs compared to the same period last year, while the sales of Yiling Pharmaceutical's cardio-cerebrovascular products in the second quarter went up, the driving force of which can mainly be attributed to the awarding of the First Prize of National Science and Technology Progress. In January this year, the research project "Establishment of a Theoretical Framework of Meridians in TCM and Guidance for Prevention and Treatment of Microangiopathy" with Research Institute of Yiling Pharmaceutical in Hebei Province, a subsidiary of Yiling Pharmaceutical, as the major research institution won the First Prize of National Science and Technology Progress in 2019, which was the only project in medical and health sector awarded First Prize in that year. Publicly available information reveals that the project conducted numerous clinical trials adopting the internationally recognized evidence-based research method and successfully resolved a huge international medical challenge: With Tongxinluo Capsule the world medical obstacle of no-reflow in patients with acute myocardial infarction was overcome; Shensong Yangxin Capsule provides a new drug for the treatment of heart failure (CHF) patients with premature ventricular contraction (PVC), filling the gap of drug treatment of sinus bradycardia with ventricular premature beats to achieve a coordinated rhythm; Qi Li Qiang Xin Capsule significantly improved the effect of clinical treatment of chronic heart failure. Having obtained this award has notably increased the market influence of the company's cardio-cerebrovascular products, thereby driving the sales of related products in the second quarter. In addition, the positive impact of the First Prize of the National Science and Technology Progress Award on the company's cardio-cerebrovascular products continues. The recently published "Chinese Expert Consensus 2020 for Ventricular Arrhythmia", jointly compiled by the Electrophysiology and Pacing Branch of Chinese Medical Association and the Professional Committee on Rhythmology of Chinese Medical Doctor Association, recommends the use of Shensong Yangxin Capsules in treating non-organic premature ventricular contractions (PVCs), organic ventricular premature beats, heart failure with ventricular premature beats, sinus bradycardia with ventricular premature beats, and the level of evidence was upgraded to Level A, which helped to further open up the market for Shensong Yangxin Capsules. In the Post-Epidemic Period, the Sales of Lianhua Qingwen also Increased Substantially During the pandemic outbreak of coronavirus disease, the "Three Drugs and Three Prescriptions" including Lianhua Qingwen were widely embraced by the public and glinted brightly on the market. A few days ago, a white paper titled "Fighting COVID-19: China in Action." released by the State Council clearly points out that Lianhua Qingwen and other traditional Chinese medicine show definite clinical effects. Lianhua Qingwen is listed as a recommended drug to treat COVID-19 and an approval was given adding COVID-19 to its indications. A clinical study regarding effects of Lianhua Qingwen in treating COVID-19 conducted by academicians such as Zhong Nanshan, Li Lanjuan and Zhang Boli and 23 hospitals confirms that the drug is safe and effective, which was published in an authoritative international journal. In the first quarter of this year, Lianhua Qingwen achieved an operating revenue of 1.542 billion Yuan with an almost doubled year-on-year increase. According to the performance forecast for the first half of the year, sales volume of Lianhua Qingwen showed a significant year-on-year growth, even when the domestic coronavirus outbreak was under control in the second quarter. A stock analyst, who wishes to remain anonymous, said that the strong growth of Lianhua Qingwen in the second quarter had, to a certain extent, revealed that this drug had become a commonly used drug in China. With Lianhua Qingwen's increasing popularity in the domestic market, its market share in traditional indications such as influenza and cold is expected to expand, which will lead to stronger growth in sales. In the meantime, Lianhua Qingwen was approved in 9 countries and regions including Brazil, Romania, Ecuador, Singapore, etc., as well as Hong Kong and Macau in China, opening up overseas markets with a breakthrough. While achieving good performance in revenue, the investment value of Yiling Pharmaceutical has also been widely recognized by many institutions. Tianfeng Securities believes that as various sectors of the company such as Chinese medicine, chemical medicine, healthcare, etc., continue to develop and the process of globalization is steadily pushed forward, they are optimistic about the future of the company. Dongxing Securities has indicated in their latest research report that the increase in the popularity of Lianhua Qingwen during the coronavirus outbreak and the expansion of indications could help to further open up rooms for more sales volume. Support from Evidence-based medicine and expansion to grassroots markets could also promote steady growths of other core products, hence a rating of "recommended" is granted.
-
China Eastern's "Fly at Will" Ticket Package for Unlimited Weekend Travel Boosts Circular Economy
SHANGHAI, July 13, 2020 /PRNewswire/ -- Over 150,000 people had enjoyed their flights under the "fly at will" air ticket discount package rolled out by China Eastern Airlines (also known as China Eastern) during the past two weekends. The passengers landing in Chongqing hold high the slogan "The world is so big. Let's take a look!" (PRNewsfoto/China Eastern Airlines) As the first-ever air ticket discount package launched in China that allows passengers to enjoy unlimited weekend flights till December 31, the "fly at will" released on June 18 was priced at 3,322 yuan (about $473.72). The product has been especially welcomed by backpackers and migrant workers. Some netizens even call it "a godsend for long-distance relationship". As the COVID-19 pandemic has been effectively brought under control in the China, 150,000 passengers flew to enjoy holidays or visit their family by using the ticket package, which has become a hot topic and a phenomenal economic activity in China. The average passenger load factor of the China Eastern flights from Shanghai to more than ten destinations rose by nearly 20 percent, with the figure of some flights even surpassing 90 percent. Some popular flights have seen the proportion of "fly at will" passengers exceed 90 percent. Although the company has dispatched wide-body aircrafts like B777 and A350 to the hot flights, it still cannot fully meet passengers' growing travel demands. The ground-breaking move has also caused social discussion. Jeff Yu, a partner in the Beijing office of consultancy Roland Berger, said that the most noteworthy part of the "fly at will" is not only the pricing or business model, but the actual test data, for which will help provide valuable insights into and support for the full recovery of the aviation field. With the "fly at will" filling a market void and driving travel demands, China Eastern is called a "pathfinder" and "wind vane" by industry insiders and media. There are by far over 20,000 pieces of news reports on the product published by more than 1,000 media outlets. Putting aside the profits and losses, "fly at will" is already a very successful product for its topicality and the publicity, pointed out Xiong Wei, a PhD candidate majoring in aviation law at McGill University. Other airlines in China have launched similar products following "fly at will". On June 21, China Express launched a similar air ticket packages. On July 1, Hainan Airlines announced that its 12 airline companies will jointly launch an air ticket package with limited destinations. China Eastern hopes that its "fly at will" can help boost businesses in tourism and hospitality, so that relevant industries can tide over the tough time together, said an executive of the service department of China Eastern. As the COVID-19 pandemic causes a marked impact on economy, a popular ticket package may lead to more positive results in consumption in relevant fields, said Xiong, noting that the social benefits of "fly at will" is already far beyond the profits it can get for the company. Image Attachments Links:Link: http://asianetnews.net/view-attachment?attach-id=367220 Caption: The passengers landing in Chongqing hold high the slogan "The world is so big. Let's take a look!"
-
Hilton Introduces Hilton EventReady with CleanStay, Setting New Standards for Event Cleanliness and Customer Service
Global Program to Deliver Innovative Solutions to Meeting Professionals as well as Peace of Mind to Attendees MCLEAN, Va.--(BUSINESS WIRE)--For more than 100 years, Hilton hotels around the world have set the stage for the world’s most coveted and important meetings, events and entertainment gatherings – from star-laden award shows and movie sets to energetic political conventions, global conferences and wow-worthy weddings. Today, that tradition continues – even at a safe distance. To address safe group travel practices and evolve today’s event experience, Hilton today announced a global, industry-leading cleanliness and customer service program specific to meetings and events. Hilton EventReady with CleanStay is the next phase of the company’s recently launched Hilton CleanStay and was shaped by extensive research and feedback. “At Hilton, we’ve always believed in the power of in-person connections and take pride in the exceptional experiences our teams create in partnership with event professionals,” said Chris Nassetta, President and CEO, Hilton. “In today’s new normal, we know that people planning and attending events of any size are focused on their health and safety. Hilton EventReady delivers innovative solutions for the entire event experience – from flexibility in planning and physical distancing protocols to transparency in cleanliness policies and inspiring catering options.” The key tenets of the Hilton EventReady with CleanStay program include: Cleanliness Protocols: The program expands on the elevated sanitation standards of the recently-announced Hilton CleanStay program, addressing every touch point of the meeting experience. This includes room seals for guest and meeting rooms, sanitizing stations in public areas and meeting spaces and EventReady Room Checklist. Book-to-Billing Flexibility: Understanding the importance of flexibility, Hilton Teams will work hand-in-hand with customers to align on shared objectives, providing: Flexible pricing, space options and contract terms; Responsive offers to meet the needs of customers, like simplified agreements for small meetings; Hilton EventReady Playbook, which delivers expert guidance and curated resources for solutions, such as Hybrid Meetings that seamlessly combine on-site attendees with those in remote locations, Room Sets and Creative Networking. Safe and Socially Responsible Solutions: To responsibly host meetings and events, Hilton Team Members will partner with their clients to achieve the meeting’s objectives while addressing both health and environmental concerns. This includes presenting creative physical distancing meeting sets and meal service, developing inspiring food & beverage options and sharing environmental impact solutions measured by LightStay, Hilton’s award-winning corporate responsibility measurement platform. Each meeting and event experience is backed by Hilton hospitality from dedicated Team Members who aim to overdeliver on client expectations from both the event professional and the attendees. For more information on Hilton EventReady with CleanStay visit www.meetings.hilton.com/eventready. ### About Hilton Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,100 properties with more than 977,000 rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton welcomed more than 3 billion guests in its 100-year history, earned a top spot on the 2019 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. Through the award-winning guest loyalty program Hilton Honors, more than 106 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including digital check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook, Twitter, LinkedIn, Instagram and YouTube. Contacts Colleen Hart Director, Global Brand Communications +1 703 883 6616 Colleen.Hart@Hilton.com
-
Amorepacific Group Launches Its Luxury Beauty Brand Sulwhasoo Across India With Nykaa
- Amorepacific Group expands its brand portfolio in India by launching Sulwhasoo with Nykaa- Sulwhasoo to present its unique vision of ageless beauty inspired by timeless wisdom to Indian customers through its innovative skincare rangeSEOUL, South Korea, July 13, 2020 /PRNewswire/ -- Global beauty company, Amorepacific Group (hereafter, Amorepacific) announced today the launch of Sulwhasoo in India. Sulwhasoo First Care Activating Serum In a bid to further its inroads into the Indian market, Amorepacific – the largest beauty company in Korea – launched its luxury beauty brand Sulwhasoo in India exclusively with Nykaa. Prior to the current Sulwhasoo launch, Amorepacific has launched its beauty brands such as innisfree in 2013, Laneige in 2018 and Etude in 2019 in India. Sulwhasoo is Amorepacific's signature luxury brand. 50 years of dedicated research on legendary Korean Ginseng and rare element from the scarce plant, Sulwhasoo formulates innovative skin solution by infusing wisdom and modern science, awake skin's radiance that is from confidence with healthy glow. Sulwhasoo Concentrated Ginseng Renewing Cream Sulwhasoo is set to spread its vision of ageless beauty inspired by timeless wisdom to the Indian market through Nykaa, the leading omni-channel beauty retailer in India. The Pan India market will be covered by the online launch of the brand from July 13, 2020. In addition, Nykaa Luxe store launch is planned for mid-August in Delhi and end of 2020 in Mumbai. The offerings in the Indian Market boasts of the brand's star product, First Care Activating Serum (1 bottle of this product is sold every 10 seconds in Korea) and other signature products such as Concentrated Ginseng Renewing line and Essential line, to name a few. The details of Sulwhasoo's two hero products are as follows: First Care Activating Serum: Launched in 1997 to inaugurate the boosting serum category, Sulwhasoo's First Care Activating Serum contains JAUM Balancing Complex™, which combines five ingredients carefully selected from 3,000 herbs in traditional Korean medicine. The Sacred Lotus, Peony, Solomon's Seal, White Lily and Rehmannia makeup up the trademarked JAUM Balancing Complex™ in this serum. The product, to be used as a first-step of skincare after washing, effectively achieves the skin balance to give a radiant glow. Concentrated Ginseng Renewing Cream: Sulwhasoo has invested in 50 years of research in order to transform the legendary ginseng ingredient into an innovative skincare solution. Sulwhasoo has made a scientific breakthrough by studying not just the ginseng root that has been recognized for its exceptional efficacies, but also its leaves, stems, flowers and berries that others have overlooked. The pinnacle of this is the Sulwhasoo's Concentrated Gingseng Renewing Cream, which works as a potent anti-aging cream. "We are delighted to introduce Amorepacific's signature brand, Sulwhasoo, in India. While Innisfree, Laneige and Etude brands are running active on Nykaa, a leading retailer in the Indian beauty market, we are pleased adding Sulwhasoo that will bring luxury skincare to our Indian consumers - with over 50 years of experience in the brand history. I believe our customers in India are going to experience Sulwhasoo's unique beauty solutions and to create more sophisticated and healthier skincare routines in future," said Michael Youngsoo Kim, Head of Amorepacific APAC RHQ. "In recent years, Nykaa has led the Korean beauty conversation in India, focusing on educating Indian customers on the novelty of the products and ingredients. This has resulted in an incremental growth of the skincare category as our customers become more demanding and discerning about their choices. We are very excited to launch Sulwhasoo in India with its unique and innovative solutions which are sure to delight our customers," said Falguni Nayar, Founder & CEO of Nykaa. As a leading global beauty company, Amorepacific furthered the popularity of Asian Beauty across the globe with its 74-year legacy and innovative, customer-centric technologies. Ranked in Forbes' list of the World's 100 Most Innovative Companies for four consecutive years, the company has transformed daily skincare routines across the globe through category innovations such Boosting Serums, Sleeping Masks and Cushion Compacts, which have disrupted the global beauty market. About Amorepacific Since 1945, Amorepacific has had a single, clear mission: to present its unique perception of beauty– namely what it calls 'Asian Beauty' – to the world. As Korea's leading Beauty Company, Amorepacific draws from its deep understanding of both nature and human to pursue harmony between inner and outer beauty. With its portfolio of over 20 cosmetics, personal care, and health care brands, Amorepacific is devoted to meeting the various lifestyles and needs of global consumers around the world: Asia, North America, Europe, Oceania and the Middle East. Amorepacific's research hubs located around the world are dedicated to sustainable R&D that combine the best of natural Asian ingredients and advanced bio-technology. With its world-class products, Amorepacific is acclaimed for the innovative ways in which it is transforming global beauty trends. https://www.apgroup.com/int/en/index.html About Sulwhasoo Brand In the year of 1966, Sulwhasoo's originator Suh Sung-Whan placed the resolution to develop cosmetic products with ginseng led to the creation of the cosmetics that was the beginning of Sulwhasoo today. Ever since the start of the brand, Sulwhasoo believes that the beauty does not deteriorate over time, instead it evolves. To encourage women be confident with healthy glow at every milestone in life, Sulwhasoo Heritage and Science Centre conducted research over 50 years on not only the Korean Ginseng, but also all 3,912 complex of traditional herbs recorded in ancient Asian medical texts, with in-depth research on women's skin of all ages. Sulwhasoo awake your radiance that is from confidence with healthy glow, by infusing wisdom with modern science. https://www.sulwhasoo.com/int/en/index.html About Nykaa Founded in 2012 by Indian entrepreneur Ms. Falguni Nayar, Nykaa was created with a vision of providing a carefully curated range of products for every beauty solution. Derived from the Sanskrit word 'Nayaka' meaning one in the spotlight, it rests on three ideals - curation, content and convenience. Nykaa currently has a portfolio of 1500+ brands across makeup, skincare, haircare & wellness offering a one-stop, personalized product availability and solutions to consumers across India. The Nykaa website and app welcome over 60 million visits per month, of which 80% are loyal repeat customers. Nykaa has created an engaged community of beauty enthusiasts across India, emerging as a leading beauty influencer through conversations on social media, emails, videos and beauty blog. The retailer currently has 68 stores across the country in two formats - Nykaa Luxe and Nykaa On Trend. https://www.nykaa.com/ Photo - https://photos.prnasia.com/prnh/20200701/2844965-1?lang=0 Photo - https://photos.prnasia.com/prnh/20200709/2844965-1-b?lang=0 Related Links :https://www.apgroup.com/int/en
-
Mitsubishi UFJ Financial Group, Inc. Announces Filing of Annual Report on Form 20-F for the Year Ended March 31, 2020
TOKYO--(BUSINESS WIRE)--Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG)(TOKYO:8306)(ISIN:JP3902900004)(MUFG) hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2020 (the “Annual Report”) with the U.S. Securities and Exchange Commission on July 10, 2020. The Annual Report includes MUFG’s audited consolidated financial statements prepared under U.S. GAAP as of and for the fiscal year ended March 31, 2020. The Annual Report is available on our website at the following website address: https://www.mufg.jp/english/ir/report/form20-f/ In addition, all shareholders may receive a hard copy of the Annual Report free of charge upon request at our website. Such request should be made to below: https://form.mufg.jp/regist/is?SMPFORM=nbp-lergt-4cdffa98f29ce1e48fbe39a625e48382 Contacts Mitsubishi UFJ Financial Group, Inc. Masahisa Takahashi, Managing Director, Head of Financial Accounting Office, Financial Planning Division Tel: +81-3-3240-8111
